Scarica l'app Stockscreener
3.17
4.97%
0.15
Dopo l'orario di chiusura:
3.16
-0.010
-0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Myriad Genetics rebuilt its AI platform after costs ballooned. Now, it can process documents in seconds. - Business Insider
Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
MYGN|Myriad Genetics Inc|Price:5.610|Chg%:-0.090 - TradingKey
Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Myriad Genetics, Inc. (MYGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance UK
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $6.14, Implies 8% Upside - TradingView
Myriad Genetics Inc (MYGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
3 Reasons MYGN is Risky and 1 Stock to Buy Instead - Yahoo Finance
Myriad Genetics stock trades sideways as investors digest recent revenue growth and precision oncolo - Ad-hoc-news.de
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 - The Manila Times
Myriad Genetics to Hold Second Quarter 2026 Earnings Conference Call on July 30 - Quiver Quantitative
AWHL vs. MYGN: Which women's health diagnostics stock is better now? - MSN
Myriad Genetics Launches New Four-in-One Prenatal Genetic Screen - Clinical Lab Products
Myriad Genetics launches prenatal genetic screening test By Investing.com - Investing.com Nigeria
Myriad Genetics launches prenatal genetic screening test - Investing.com
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen - The Manila Times
Myriad's one-draw test runs four prenatal screens at 8 weeks - Stock Titan
Burning Rock and Myriad Announce Global Strategic Technology Licensing Partnership to Expand HRD Testing Worldwide - EIN News
ETFs Investing in Myriad Genetics, Inc. Stocks - TradingView
AWHL vs. MYGN: Which Women's Health Diagnostics Stock is Better Now? - The Globe and Mail
MYGN Stock Price, Quote & Chart - ChartMill
Myriad Genetics reports FirstGene prenatal screen achieves over 98 percent sensitivity and 99 percent specificity - Traders Union
Is This the Right Time to Hold MYGN Stock in Your Portfolio? - Yahoo Finance
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - qz.com
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Announces Target Price $4 - Moomoo
Myriad Genetics (MYGN) Q4 2024 earnings summary - Quartr
Myriad Genetics (MYGN) Proxy filing Summary - Quartr
AI upgrade boosts Prolaris Test predictive power at Myriad Genetics - Traders Union
(MYGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Myriad Genetics (MYGN) Surges 3.5%: Approaching Resistance at $6.51ADD Alert - dars.gov.et
Myriad Genetics Q1 2026 Earnings: EPS Miss Clouds Diagnostic Growth OutlookGross Profit Margin - dars.gov.et
Meta-analysis confirms Myriad's Prolaris test e... - Pluang
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer - 富途牛牛
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer - Yahoo Finance
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS - BioSpace
Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa
MYGNMyriad Genetics Inc Latest SEC Filings - Finviz
Sera Prognostics adds former Myriad Genetics CEO to board - Investing.com
Sera Prognostics adds former Myriad CEO Mark Capone to board - Stock Titan
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance
(MYGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Price to sales forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Price to book forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Myriad Genetics, Inc. Actuals & Estimates (NASDAQ:MYGN) - TradingView
0.76%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):